Compare BCG & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCG | LSTA |
|---|---|---|
| Founded | 2016 | 1980 |
| Country | United States | United States |
| Employees | 150 | N/A |
| Industry | | Misc Health and Biotechnology Services |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.6M | 28.9M |
| IPO Year | N/A | 2000 |
| Metric | BCG | LSTA |
|---|---|---|
| Price | $1.69 | $3.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 80.2K | 48.7K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $56.15 | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $1.36 | $1.81 |
| 52 Week High | $3.44 | $5.07 |
| Indicator | BCG | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 35.88 | 37.39 |
| Support Level | $1.46 | $2.75 |
| Resistance Level | $1.90 | $3.41 |
| Average True Range (ATR) | 0.19 | 0.14 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 5.62 | 31.71 |
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.